Endothelial cells (EC) and endothelial precursor cells (EPC) kinetics in hematological patients undergoing chemotherapy or autologous stem cell transplantation (ASCT)
Language English Country England, Great Britain Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21136582
DOI
10.1002/hon.941
Knihovny.cz E-resources
- MeSH
- Colony-Forming Units Assay MeSH
- AC133 Antigen MeSH
- CD146 Antigen blood MeSH
- Platelet Endothelial Cell Adhesion Molecule-1 blood MeSH
- Antigens, CD34 blood MeSH
- Transplantation, Autologous MeSH
- Antigens, CD blood MeSH
- Endothelial Cells metabolism pathology MeSH
- Drug Therapy methods MeSH
- Glycoproteins blood MeSH
- Hematologic Neoplasms blood drug therapy surgery MeSH
- Stem Cells metabolism pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Peptides blood MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Flow Cytometry MeSH
- Vascular Endothelial Growth Factor Receptor-2 blood MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Hematopoietic Stem Cell Transplantation methods MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- AC133 Antigen MeSH
- CD146 Antigen MeSH
- Platelet Endothelial Cell Adhesion Molecule-1 MeSH
- Antigens, CD34 MeSH
- Antigens, CD MeSH
- Glycoproteins MeSH
- Peptides MeSH
- PROM1 protein, human MeSH Browser
- Vascular Endothelial Growth Factor Receptor-2 MeSH
Our objective was to study the kinetics of circulating endothelial cells (EC) and endothelial precursor cells (EPC) in hematological patients during chemotherapy and autologous stem cell transplantion (ASCT). Eighteen newly diagnosed patients and 17 patients undergoing ASCT were studied and compared to healthy controls. ECs were evaluated as CD146+CD31+Lin- cells, while EPCs were evaluated as CD34+CD133+Lin-, or CD34+VEGFR2+Lin- cells, or CFU-En colony forming units. Numbers of these cells were evaluated before and after treatment, and, in patients treated with ASCT, during mobilization of hematopoietic progenitors. Both newly diagnosed patients and patients before ASCT had significantly higher number of CD146+CD31+Lin- cells and significantly lower number of CFU-En colonies than healthy controls. These parameters did not return to normal for at least 3 months after chemotherapy or ASCT. Numbers of CFU-En did not correlate either with numbers of CD34+CD133+Lin- cells or with numbers of CD34+VEGFR2+Lin- cells but they did correlate with numbers of CD4+ lymphocytes and NK cells. In conclusion, we have found that hematological patients have higher number of EC and lower numbers of CFU-En than healthy controls and that these parameters do not return to normal after short-term follow-up. Furthermore, our observations support emerging data that CFU-En represent cell population different from flowcytometrically defined EC and endothelial precursors and that their development requires cooperation of monocytes and CD4+ lymphocytes. However, cells forming CFU-En express endothelial surface markers and can contribute to proper endothelial function by NO production.
References provided by Crossref.org
